Tramadol

Vad är Tramadol?

Tramadol hydrochloride is a centrally acting opioid analgesic used for the management of moderate to moderately severe pain in adults. It has a dual mechanism of action, combining opioid receptor activity with inhibition of monoamine reuptake. Tramadol is a prescription-only controlled medicine in the majority of EU-medlemsländer and is available in immediate-release and modified-release formulations.

Hur fungerar Tramadol work?

Tramadol’s analgesic effect results from two complementary mechanisms that work synergistically:

• Opioid receptor agonism: Tramadol and its active metabolite O-desmethyltramadol (M1) bind to mu-opioid receptors in the central nervous system, inhibiting the ascending transmission of pain signals and modulating pain perception. The M1 metabolite has approximately 200 times the affinity for mu-opioid receptors compared to the parent compound.
• Monoamine reuptake inhibition: Tramadol inhibits the reuptake of serotonin and noradrenaline (norepinephrine) in the central nervous system, pathways that are central to the body’s descending pain-modulation system. This component contributes to tramadol’s efficacy in neuropathic pain.
• Combined analgesia: The interaction between these two mechanisms provides a broader analgesic profile than pure opioids, with some evidence of effectiveness in conditions such as diabetic neuropathy and fibromyalgia.

The extent of the opioid component depends partly on CYP2D6 metabolism. Poor metabolisers produce less M1 metabolite and may experience reduced analgesia; ultra-rapid metabolisers may experience heightened opioid effects.

Vem är Tramadol for?

Tramadol is indicated for adults (18 years and over) with moderate to moderately severe pain that is not adequately managed by non-opioid analgesics. Clinical indications typically include:

• Musculoskeletal pain: Severe back pain, joint pain, or soft tissue injuries not responding to NSAIDs or weaker analgesics
• Post-operative pain: Pain following surgical procedures requiring more than mild analgesia
• Neuropathic pain: Pain arising from nerve damage or dysfunction, such as diabetic peripheral neuropathy, postherpetic neuralgia, or radiculopathy
• Cancer-related pain: As part of the WHO analgesic ladder for moderate pain
• Chronic pain conditions: Under specialist supervision when other treatments have been insufficient

Tramadol is not appropriate for children, patients with epilepsy or a lowered seizure threshold, patients taking MAO inhibitors, those in acute opioid withdrawal, and patients with acute intoxication by alcohol, hypnotics, or psychotropic medicines. A full medical assessment is required before any prescription is issued.

Dosering

Tramadol is available in immediate-release (IR) and modified-release (MR) formulations. The choice between formulations and the dosing schedule should be determined by a doctor based on the patient’s pain pattern and needs.

Formulation	Starting Dose	Titration	Maximum Daily Dose
Immediate-release (capsules/tablets)	50–100 mg every 4–6 hours	Increase as needed under supervision	400 mg/day
Modified-release (tablets)	100–150 mg twice daily	Increase as clinically needed	400 mg/day
Elderly patients (>75 years)	Lower starting doses	Slower titration	300 mg/day (guidance varies)

Modified-release tablets must be swallowed whole — they must never be crushed, chewed, or broken, as this releases the full dose immediately and risks serious opioid toxicity.

Tramadol should be used at the lowest effective dose for the shortest duration consistent with the patient’s treatment goals.

Biverkningar

As with all opioid medicines, Tramadol carries important risks that patients and prescribers should weigh carefully against the benefits of treatment.

Vanliga biverkningar (kan drabba fler än 1 av 10 personer)

• Nausea (very common, particularly on initiation)
• Dizziness and vertigo
• Headache
• Drowsiness and sedation
• Constipation
• Dry mouth
• Sweating

Mindre vanliga but serious side effects

• Seizures: Tramadol lowers the seizure threshold and can cause convulsions, particularly at higher doses, in patients with epilepsy, or when combined with medications that lower the seizure threshold (antidepressants, antipsychotics, bupropion). This is one of tramadol’s most clinically significant risks.
• Serotonin syndrome: The combination of tramadol’s serotonin reuptake inhibition with SSRIs, SNRIs, MAO inhibitors, triptans, or linezolid can trigger serotonin syndrome — a potentially life-threatening condition characterised by agitation, confusion, rapid heart rate, high temperature, and muscle rigidity.
• Dependence and withdrawal: Physical and psychological dependence can develop with regular use. Abrupt discontinuation should be avoided; tapering under medical supervision is recommended.
• Respiratory depression: At high doses or when combined with other CNS depressants, tramadol can dangerously suppress breathing.
• Hypoglycaemia: Cases of hypoglycaemia have been reported in patients taking tramadol.

This is not a complete list of side effects. Refer to the EMA-approved Summary of Product Characteristics for full prescribing details.

Hur får man Tramadol online i Europa

Tramadol is a prescription-only controlled medicine in most EU-medlemsländer. It cannot be legally dispensed without a valid prescription from a licensed medical professional.

Prescrivia operates as a technology intermediary platform: we do not prescribe medicines, employ doctors, or sell medicines. Our platform connects patients with independent EU-registered doctors who can conduct confidential online health assessments.

The process works as follows:

1. Fyll i en hälsobedömning: Answer a structured set of health questions covering your medical history, current medications (particularly any serotonergic medicines or CNS depressants), pain history, and prior analgesic use.
2. Läkarbedömning: An independent EU-registered doctor reviews your assessment. If Tramadol is clinically appropriate for your situation, they may issue a prescription. If it is not appropriate — or if a safer alternative exists — the doctor will advise accordingly.
3. Recept och leverans: If a prescription is issued, it is forwarded to a licensed EU pharmacy partner, which dispenses and ships the medicine directly to you.

Important: Prescrivia garanterar inte that a prescription will be issued. All prescribing decisions are made independently by qualified medical professionals based on your individual clinical circumstances.

Viktig säkerhetsinformation

Använd inte Tramadol if you:

• Are under 18 years of age
• Have epilepsy or a history of seizures
• Are taking or have recently taken MAO inhibitors (within 14 days)
• Are in acute opioid withdrawal
• Have acute alcohol intoxication or are under the influence of hypnotics, opioid analgesics, or psychotropic medicines
• Are known to be an ultra-rapid CYP2D6 metaboliser and at risk of serotonin toxicity

Berätta för din läkare before starting Tramadol if you have:

• A personal or family history of epilepsy or seizures
• A history of opioid dependence or substance misuse
• Liver or kidney disease
• Head injury or raised intracranial pressure
• Depression, anxiety, or are taking any antidepressant medication
• Adrenal insufficiency or hypothyroidism
• Prostate enlargement or urinary retention

Läkemedelsinteraktioner: Tramadol has clinically significant interactions with SSRIs, SNRIs, MAO inhibitors, triptans, linezolid (risk of serotonin syndrome), anticoagulants (warfarin — risk of altered INR), CYP2D6 and CYP3A4 inhibitors and inducers, antiepileptics (carbamazepine reduces tramadol efficacy), and other CNS depressants including alcohol and benzodiazepines. Always disclose all current medications to your doctor during the assessment.

Modified-release tablets must never be crushed, broken, or chewed.

Källor

Medical information on this page is based on the following sources:

• Europeiska läkemedelsmyndigheten (EMA). Tramadol hydrochloride — Summary of Product Characteristics. Available at: ema.europa.eu
• Världshälsoorganisationen (WHO). WHO Model List of Essential Medicines — Medicines for pain and palliative care. who.int
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
• Shadnia S, et al. Tramadol intoxication: A review of 114 cases. Hum Exp Toxicol. 2008.

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.